Invivyd ( (IVVD) ) has released its Q3 earnings. Here is a breakdown of the information Invivyd presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Invivyd, Inc. is a biopharmaceutical company focused on developing monoclonal antibodies for the prevention and treatment of viral infectious diseases, particularly SARS-CoV-2, using a proprietary technology platform.
In its third-quarter 2025 earnings report, Invivyd reported a notable increase in revenue driven by its product PEMGARDA, alongside strategic advancements in its clinical programs, particularly the upcoming pivotal trials for VYD2311, a vaccine-alternative antibody for COVID-19 prevention.
Key financial highlights include a 41% year-over-year increase in PEMGARDA’s net product revenue, reaching $13.1 million, and a strong cash position with over $100 million in cash and equivalents by October 2025. The company also announced the FDA’s clearance for its IND application for VYD2311, setting the stage for the REVOLUTION clinical program, which aims to evaluate the safety and efficacy of this novel antibody.
Strategically, Invivyd is preparing for the commercial launch of VYD2311, pending approval, and is expanding its pipeline to target other pathogens beyond COVID-19. The company also strengthened its leadership team with new appointments and secured significant funding through a public offering.
Looking ahead, Invivyd is positioned to advance its clinical trials and potentially expand its market presence with VYD2311, while continuing to explore opportunities for pipeline expansion beyond SARS-CoV-2.